



Invesco S&P World Health Care ESG UCITS ETF

Supplement to the Prospectus

This Supplement forms part of and must be read in conjunction with the Prospectus. The Supplement may not be distributed unless accompanied by the Prospectus. As at the date of this Supplement, the Prospectus is dated 9 September 2026. However, investors should note that the Prospectus may be amended, supplemented or modified from time to time. For the most current version of the Prospectus, investors should refer to etf.invesco.com.

THIS DOCUMENT IS IMPORTANT. YOU SHOULD NOT PURCHASE SHARES IN THE FUND DESCRIBED IN THIS SUPPLEMENT UNLESS YOU HAVE ENSURED THAT YOU FULLY UNDERSTAND THE NATURE OF SUCH AN INVESTMENT AND THE RISKS INVOLVED AND ARE SATISFIED THAT THE INVESTMENT IS SUITED TO YOUR CIRCUMSTANCES AND OBJECTIVES, THE RISKS INVOLVED AND YOUR OWN PERSONAL CIRCUMSTANCES. IF YOU ARE IN ANY DOUBT ABOUT THE CONTENTS OF THIS SUPPLEMENT YOU SHOULD TAKE ADVICE FROM AN APPROPRIATELY QUALIFIED ADVISOR.

Capitalised terms used in this Supplement will have the meanings given to them in the Definitions section below or in the Prospectus.

Invesco Markets II plc

An umbrella fund with segregated liability between the sub-funds

Dated 9 September 2026

IMPORTANT INFORMATION

Suitability of Investment

Please review the information in the Prospectus regarding suitability of an investment.

The Shares are not principal protected. The value of the Shares may go up or down and you may not get back the amount you have invested. See the section headed "Risk Factors" of the Prospectus and the section headed "Other Information – Risk Factors" of this Supplement for a discussion of certain risks that should be considered by you.

In addition to investing in transferable securities, the Company may invest on behalf of the Fund in financial derivative instruments ("FDIs"), where applicable. Certain risks attached to investments in FDIs are set out in the Prospectus under "Risk Factors".

Prospective investors should refer to the annex to this Supplement regarding the Fund's environmental and / or social characteristics.

The Shares purchased on the Secondary Market cannot usually be sold directly back to the Fund. Investors must buy and sell Shares on a Secondary Market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying Shares and may receive less than the current net asset value when selling them.

Profile of a typical investor

A typical investor would be one who is a private or institutional investor and is seeking capital appreciation over the long term. Such an investor is also one that is able to assess the merits and risks of an investment in the Shares.

General

This Supplement sets out information in relation to the Shares and the Fund. You must also refer to the Prospectus which is separate to this document and describes the Company and provides general information about offers of shares in the Company. You should not take any action in respect of the Shares unless you have received a copy of the Prospectus. Should there be any inconsistency between the contents of the Prospectus and this Supplement, the contents of this Supplement will, to the extent of any such inconsistency, prevail. This Supplement and the Prospectus should both be carefully read in their entirety before any investment decision with respect to Shares is made.

Definitions

Words and expressions defined in the Prospectus will, unless otherwise defined in this Supplement, have the same meaning when used in this Supplement.

TERMS OF THE SHARES REPRESENTING INTERESTS IN THE FUND

Investment Objective of the Fund

The investment objective of the Fund is to achieve the net total return of the S&P World ESG Enhanced Health Care Index (the "**Reference Index**") less fees, expenses and transaction costs.

Investment Policy of the Fund

Further information on the components and selection criteria of the Reference Index is set out below under "**General Description of the Reference Index**".

The Fund will employ a Replication Strategy.

In order to replicate the Reference Index, the Fund may invest up to 20% of its Net Asset Value in shares issued by the same body.

This limit may be raised to 35% for a single issuer in exceptional market circumstances, for example, market dominance. Market dominance exists where a particular component of the Reference Index has a dominant position in the particular market sector or geographical region in which it operates and as a result accounts for a large proportion of the Reference Index. This means that the Fund may have a high concentration of investment in a particular issuer.

Further information in relation to how the Fund will seek to track the Reference Index is set out in the sections titled **"Investment Objective and Policies"** and **"Investment Restrictions and Permitted Investments"** in the Prospectus.

There are a number of circumstances where gaining access to the components of the Reference Index may be prohibited by regulation, may not otherwise be in the Shareholders' interests or may not otherwise be possible or practicable, as set out in the Prospectus.

The Fund may hold ancillary liquid assets (namely cash and UCITS money market funds) and use efficient portfolio management techniques in accordance with the requirements of the Central Bank.

The Fund may also engage in transactions in FDIs for hedging and/or efficient portfolio management purposes. The Fund may use the following FDIs listed on a Market or traded OTC, as applicable: options and futures transactions, forward contracts, non-deliverable forwards and spot foreign exchange transactions. Further details on FDIs and how they may be used are set out in the section titled "Appendix III – Efficient Portfolio Management and Use of Financial Derivative Instruments" in the Prospectus.

Further information relevant to the Fund's investment policy is set out in the sections titled **"Investment Objectives & Policies"** and **"Investment Restrictions and Permitted Investments"** in the Prospectus.

Investment Restrictions of the Fund

The general investment restrictions set out under **"Investment Restrictions and Permitted Investments"** in the Prospectus apply to the Fund.

The Fund shall not invest more than 10% of its net assets in other UCITS, open ended CIS or closed ended collective investment funds that meet the requirements of the Central Bank (and, in the case of closed ended collective investment funds, that qualify as transferable securities).

With the exception of permitted investment in unlisted securities or in units of open-ended CIS, investment will be limited to the stock exchanges and regulated markets set out in Appendix I of the Prospectus.

Index Tracking

It is anticipated that the Tracking Error, as measured using the unhedged Share Classes, will be between 0% and 1.00% under normal market conditions. However, exceptional circumstances may arise which cause the Fund's Tracking Error to exceed 1.00%.

Efficient Portfolio Management

Further information on efficient portfolio management techniques that may be used by the Fund is contained in the **"Securities Financing Transactions"** section below and in the main body of the Prospectus under the heading **"Appendix III – Efficient Portfolio Management and Use of Financial Derivative Instruments"**.

Securities Financing Transactions

The Fund may use Securities Financing Transactions, namely securities lending.

The type of assets that may be held by the Fund in accordance with its investment objective and policies and may be subject to such Securities Financing Transactions are equities. The maximum proportion of the Fund's assets that may be subject to securities lending is 100%, and the expected proportion of the

Fund's assets that may be subject to securities lending is between 0% and 30%. Please refer to the Prospectus section "Securities Financing Transaction" for further details.

All securities of the Fund are subject to specific securities lending criteria established for ESG funds which stipulates that (a) securities are to be recalled over voting dates and (b) applies a more restrictive eligible collateral schedule than non ESG funds.

Transparency of the Promotion of Environmental or Social Characteristics

The Fund is an Article 8 Fund (as defined in the Prospectus).

The Fund promotes environmental and social characteristics, namely to provide exposure to a risk and return profile of the Parent Index, gaining exposure to corresponding sectors whilst improving ESG (environmental, social and governance) characteristics and reducing carbon emissions. The Fund achieves this by replicating the Reference Index, which has a methodology that is consistent with attaining the environmental and social characteristics promoted by the Fund.

Further information on how the environmental and social characteristics promoted by the Fund are achieved is set out under the heading "**General Description of the Reference Index**" below.

The strategy of the Fund is to replicate the Reference Index. As the Fund is passively managed, management of the portfolio does not include any separate integration of sustainability risks into the investment process. Sustainability risks were considered in the selection of the Reference Index for use by the Fund and sustainability risks may be integrated at the level of the Reference Index as described in the section of this Supplement titled "**General Description of the Reference Index**". However, as the main strategy of the Fund is to replicate the Reference Index, the Manager deems that further consideration of sustainability risks is not relevant to the strategy of the Fund and the likely impact of sustainability risks on returns is not assessed.

The Fund generally expects to invest a portion of its assets in sustainable investments. The investments underlying the Fund, however, do not currently take into account the EU criteria for environmentally sustainable economic activities as defined in Regulation (EU) 2020/852 on the establishment of a framework to facilitate sustainable investment (the "**Taxonomy Regulation**") and so the "do no significant harm" principle under the Taxonomy Regulation does not currently apply to the investments underlying the Fund. At the date of this Supplement, 0% of the Fund's investments will be aligned with the environmental objectives under the Taxonomy Regulation. The Manager will keep the Fund's position vis-à-vis the Taxonomy Regulation under consideration and, to the extent required, the Supplement will be amended accordingly.

The extent to which principal adverse impacts are considered under Article 7 of SFDR is set out in the annex to this Supplement. Further information on the consideration of principal adverse impacts can be found in the annual report.

Currency Hedging Policy

The Fund may enter into transactions for the purposes of hedging the foreign exchange exposure in any hedged Share Classes (identified by "**Hdg**" in their names).

The Fund may enter into transactions for the purposes of hedging the foreign exchange exposure of the currency or currencies in which the underlying assets of the Fund are denominated to the currency of a Share Class (identified by "**PfHdg**" in their names).

Further information on currency hedging at Share Class level is set out in the section titled "**Hedged Classes**" in the Prospectus.

Borrowing and Leverage

The Company on behalf of the Fund may borrow up to 10% of the Net Asset Value of the Fund on a temporary basis. Further information on borrowing and leverage is set out in the sections titled "**Borrowing and Lending Powers**" and "**Leverage**" in the Prospectus.

The Company will use the commitment approach for the purposes of calculating global exposure for the Fund. The Fund's total exposure to the Reference Index will be limited to 100% of Net Asset Value.

While it is not the Investment Manager's intention to leverage the Fund, any leverage resulting from the

use of FDIs will be done in accordance with the Regulations.

Dividend Policy

Dividends will be declared on a quarterly basis for the Dist Shares, the EUR PfHdg Dist Shares, the GBP PfHdg Dist Shares, the CHF PfHdg Dist Shares, the MXN PfHdg Dist Shares, and the SEK PfHdg Dist Shares in accordance with the general provisions set out in the Prospectus under the heading "Dividend Policy" and Shareholders will be notified in advance of the date on which dividends will be paid. Distributions will not be made in respect of the Acc Shares, the EUR PfHdg Acc Shares, the GBP PfHdg Acc Shares, the CHF PfHdg Acc Shares, the MXN PfHdg Acc Shares, and the SEK PfHdg Acc Shares and income and other profits will be accumulated and reinvested.

Trading

Application will be made to Euronext Dublin and/or the London Stock Exchange and/or Deutsche Borse and/or such other Relevant Stock Exchanges for listing and/or admission to trading of the Shares issued and available to be issued on the main market of each of the Relevant Stock Exchanges on or about the Launch Date. This Supplement and the Prospectus together comprise listing particulars for the purposes of trading on the main market of each of the Relevant Stock Exchanges.

Exchange Traded Fund

The Fund is an ETF. The Shares of the Fund are fully transferable among investors and will be listed and/or traded on the Relevant Stock Exchanges. It is envisaged that Shares will be bought and sold by private and institutional investors in the Secondary Market in the same way as the ordinary shares of a listed trading company.

Investors should refer to the section of the Prospectus titled "**Subscriptions and Redemptions**" for information of how to deal in Shares.

General Information Relating to the Fund

Type	Open-ended.
Base Currency	USD
Business Day	A day (other than a Saturday or Sunday) on which the United States Federal Reserve System is open or such other day or days that the Directors may determine and notify to Shareholders in advance.
Dealing Day	Any Business Day. However, some Business Days will not be Dealing Days where, for example, markets on which the Fund's Assets are listed or traded or markets relevant to the Reference Index are closed provided there is at least one Dealing Day per fortnight, subject always to the Directors' discretion to temporarily suspend the determination of the Net Asset Value and the sale, conversion and/or redemption of Shares in the Company or any Fund in accordance with the provisions of the Prospectus and the Articles. The Investment Manager produces dealing calendars which detail in advance the Dealing Days for each Fund. The dealing calendar may be amended from time to time by the Investment Manager where, for example, the relevant market operator, regulator or exchange (as applicable) declares a relevant market closed for trading and/or settlement (such closure may be made with little or no notice to the Investment Manager). The dealing calendar for the Fund is available from the Manager.

Dealing Deadline	4:30pm (Dublin time) one Business Day before the relevant Dealing Day or such other time as the Investment Manager may, in consultation with the Directors, determine and is notified to Shareholders by the Company provided always that the Dealing Deadline will be before the Valuation Point. No subscription, exchange or redemption applications may be accepted after the Valuation Point.
Subscriptions, Exchanges and Repurchases	All subscriptions, exchanges and repurchases can only take place through an Authorised Participant or other representative appointed by the Company in the relevant jurisdiction.
Launch Date	14 September 2023 in respect of Class Acc Shares.
Liquidity Management Tools	The Manager has selected the liquidity management tools set out in the section of the Prospectus titled " Liquidity Management Tools " to manage the Fund's liquidity risk under different market conditions.
Initial Offer Period	The Initial Offer Period in respect of unlaunched Shares will start at 9.00 a.m. (Dublin time) on 10 September 2026 and close at 5.00 p.m. (Dublin time) on 9 March 2027 or such earlier or later date as the Directors may determine.
Initial Issue Price	An appropriate fraction of the official closing level of the Reference Index on the Business Day preceding the launch date of the relevant Class. Investors should note that the Initial Issue Price of the Shares on the Launch Date of the relevant Share Class will be available on etf.invesco.com .
Valuation Point	10.30 pm (Dublin time) on the relevant Dealing Day by reference to which the Net Asset Value per Share of the Fund is determined. At all times the Valuation Point will be after the Dealing Deadline. The value of any investments which are listed or dealt on a Market shall be the closing price on the relevant Market at the Valuation Point.
Settlement Date	By the second Business Day after the relevant Dealing Day (or such other day as the Directors (or their delegate) may determine and notify in advance to the applicant).

The Shares

The Share Classes available for subscription in the Fund are set out in "**Appendix I – Description of the Shares**". Additional Share Classes may be added to the Fund, subject to prior notification to and the approval of the Central Bank, and will be set out in a revised supplement.

Intra-Day Portfolio Value ("iNAV")

Information on intra-day portfolio value is contained in the main body of the Prospectus under the heading "**Intra-Day Portfolio Value**".

Fees and Expenses

This section titled "**Fees and Expenses**" should be read in conjunction with the section titled "**Fees & Expenses**" in the Prospectus.

The Management Fee that will be incurred by the Company on behalf of the Fund and will affect the Net Asset Value of the relevant Share Class of the Fund are set out in "**Appendix I – Description of the Shares**".

The following fees will be incurred on each Share by Shareholders (which accordingly will not be incurred

by the Company on behalf the Fund and will not affect the Net Asset Value of the Fund):

Share Class	All Share Classes
Subscription Charge	Up to 5%
Redemption Charge	Up to 3%

The Subscription Charge is deducted from the investment amount received from an investor for subscription for Shares. Such Subscription Charge is payable to the Manager.

Exchange of Shares

Shareholders may apply to exchange on any Dealing Day all or part of their holding of Shares of any Class of the Fund (the "**Original Class**") for Shares of another Class of the Fund which is being offered at that time (the "**New Class**") provided that all the criteria for applying for Shares in the New Class have been met.

The general provisions and procedures relating to redemptions will apply equally to exchanges. All exchanges will be treated as a redemption of the Shares of the Original Class and application to the purchase of Shares of the New Class, save that no Subscription Charge or Redemption Charge will be payable. Exchanges of Shares may be subject to an Exchange Charge of up to 3% of the Repurchase Price for the total number of Shares in the Original Class to be repurchased.

German Investment Tax Act 2018

In accordance with the German Investment Tax Act (Investmentsteuergesetz), as amended from time to time ("**GITA**"), the Fund intends to qualify as an equity fund (Aktienfonds) as defined in section 2 para 6 GITA, and will continuously invest more than 50% of its Net Asset Value (as defined in section 2 para. 9b sent. 2 and 3 GITA) into equities (as defined in section 2 para 8 GITA).

GENERAL DESCRIPTION OF THE REFERENCE INDEX

The Reference Index tracks the performance of large and mid-capitalisation Health Care companies in developed markets, and through a combination of exclusions and by re-weighting constituents' free-float market capitalisation weights based upon certain environmental, social and governance ("**ESG**") metrics, seeks to collectively enhance the Reference Index's ESG profile and reduce its carbon footprint, relative to the S&P World Health Care Index (the "**Parent Index**").

The Reference Index is further described below but only represents an extract of information available from public sources and neither the Directors, the Manager, S&P Dow Jones Indices LLC or such other successor sponsor to the Reference Index (the "**Index Provider**") nor the Investment Manager take any responsibility for the accuracy or completeness of such information.

The Parent Index is a free float-adjusted market capitalisation weighted index which aims to measure the performance of companies in the S&P World Index that are classified as Health Care according to the Index Provider's sector classification.

The Reference Index is constructed from the Parent Index by using the Index Provider's exclusionary criteria to exclude from the Parent Index on a quarterly basis (per the Index Rebalancing and Weighting section) securities of issuers that:

- (i) are involved (as defined by the Index Provider) in the following business activities: tobacco, controversial weapons, thermal coal (including hard coal and lignite), oil sands, oil fuels, gaseous fuels, power generation from sources with high greenhouse gas intensity, small arms and military contracting; and are classified as Non-Compliant according to the United Nations Global Compact (UNGC) principles

Further, the Reference Index excludes on a semi-annual basis (per the Index Rebalancing and Weighting section) securities of issuers that:

- (i) do not have an S&P Global ESG Score;
- (ii) do not have carbon intensity data;
- (iii) have an S&P Global ESG Score that falls within the lowest 20% of ESG scores by stock count of the Parent Index; and
- (iv) have carbon intensity levels that rank in the worst 10% of companies by free-float market cap per Industry Group (according to the Index Provider's sector classification) of the Parent Index and in the worst 10% of companies by free-float market cap in the S&P World Index.

Securities are also excluded if the Index Provider's Reference Index Committee decides to remove them following an evaluation of the potential impact of controversial company activities raised by an S&P Media and Stakeholder Analysis Report (that flags any company as facing potential ESG risk incidents and/or controversial activities); securities can be excluded immediately, intra-rebalance, if deemed appropriate.

The exclusion criteria of the Reference Index is aligned with the exclusions for Paris-aligned Benchmarks detailed in Article 12(1)(a) – (g) of Commission Delegated Regulation (EU) 2020/1818.

Involvement and revenue thresholds are defined by the Index Provider. Further information in relation to the revenue thresholds and scoring criteria, can be obtained from the Index Provider's website.

The Reference Index then applies an optimisation approach to re-weight remaining eligible securities with a view to achieving: 1) an uplift in the weighted average S&P Global ESG Score, relative to the Parent Index, such that the weighted average S&P Global ESG Score of the Reference Index is equivalent to a score that would be achieved if the 25% lowest scoring stocks by free-float market cap per Industry Group (according to the Index Provider's sector classification) were removed from the Parent Index; 2) the maximum of either a 30% decrease in the weighted average carbon intensity relative to the Parent Index, or the weighted average carbon intensity equivalent to the removal of securities that have carbon intensity levels that rank in the worst 25% of companies by free-float market cap per Industry Group (according to the Index Provider's sector classification) of the Parent Index and in the worst 25% of companies by free-float market cap in the S&P World Index.

The above optimisation is subject to the following constraints: 1) the weighted average S&P Global ESG Score cannot be lower than that of the Parent Index after removing the lowest 20% of ESG scores by stock count; 2) the weight of each individual constituent will not be overweighted by more than 5% relative to its weight in the Parent Index; 3) the weight of each individual constituent will not be overweighted by more than 10 times its relative weight in the Parent Index; 4) a floor of 0.01% will be applied such that eligible constituents with weights below the floor are excluded from the Reference Index; and 5) at each semi-annual rebalance there is a maximum turnover limit applied unless it is not possible for the optimisation targets, detailed above, to be achieved without a significant deviation from the targeted level for each, in which case this turnover constraint is relaxed in stages, and then removed entirely if no feasible solution can be found.

Capitalised terms used above and not defined herein are defined by the Index Provider. Further information on these terms and the Reference Index methodology can be found on the Index Provider's website. This document provides a summary of the principal features of the Reference Index; the complete description of the Reference Index shall at all times prevail.

Index Rebalancing

The Reference Index rebalances on a semi-annual basis and is effective after the close of the last business day of April and October (each an "Index Rebalancing Date"). On each Index Rebalancing Date, the weights of the securities comprising the Reference Index are re-calculated by the Index Provider by applying all of the exclusionary criteria and the optimisation approach described above. On a quarterly basis between Index Rebalancing Dates, the Index Provider assesses the compliance of the securities comprising the Reference Index with some of the ESG criteria described above (each an "Index Review Date"). On each Index Review Date, securities may be removed from the Reference Index if such securities breach the exclusionary screens (i) and (ii) set out above. Securities may also be removed from the Reference Index outside of an Index Review Date, if assessed to by the Index Provider to be in breach of the exclusionary screen set out in (ii) above. Furthermore, the weights of the constituents that comprise the Reference Index are reviewed on a semi-annual, quarterly and mid-quarterly basis. If the largest constituent in the Reference Index exceeds 33% or the second largest constituent weight exceeds 19%, the weight of the largest company in the Reference Index will be capped at 31.5% and the weight of all other companies in the Reference Index will be capped at 18%.

The Fund will bear the costs of any rebalancing trades (i.e. the costs of buying and selling securities of the

Reference Index and associated taxes and transaction costs).

Index Provider and Website

The Reference Index is sponsored by S&P Dow Jones Indices LLC and more details on the Reference Index can be found at: <https://www.spglobal.com/spdji/en/supplemental-data/europe/>.

Publication

The level of the Reference Index will be published on: <https://www.spglobal.com/spdji/en/supplemental-data/europe/>.

OTHER INFORMATION

Risk Factors

Certain risks relating to the Shares are set out in the section titled "**Risk Factors**" in the Prospectus. In addition, Shareholders should note the following risks that apply:

Risks
Environmental, Social and Governance Risk
Concentration Risk

Investors should also refer to the Prospectus for additional disclosure of risks and conflicts of interest.

Disclaimers

THE DIRECTORS OF THE COMPANY, THE MANAGER, THE INVESTMENT MANAGER AND THE INDEX PROVIDER TOGETHER THE "RESPONSIBLE PARTIES" DO NOT GUARANTEE THE ACCURACY AND/OR THE COMPLETENESS OF ANY DESCRIPTION RELATING TO THE REFERENCE INDEX OR ANY DATA INCLUDED THEREIN AND THE RESPONSIBLE PARTIES SHALL HAVE NO LIABILITY FOR ANY ERRORS, OMISSIONS, OR INTERRUPTIONS THEREIN. THE RESPONSIBLE PARTIES MAKE NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE FUND, TO ANY SHAREHOLDER IN THE FUND, OR TO ANY OTHER PERSON OR ENTITY IN RESPECT OF THE REFERENCE INDEX DESCRIBED HEREIN.

THE INDEX PROVIDER MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE WITH RESPECT TO THE REFERENCE INDEX OR STRATEGY OR ANY DATA INCLUDED HEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL THE INDEX PROVIDER HAVE ANY LIABILITY FOR ANY SPECIAL, PUNITIVE, INDIRECT, OR CONSEQUENTIAL DAMAGES OR FOR ANY LOST PROFITS, EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES.

THE "S&P WORLD ESG ENHANCED HEALTH CARE INDEX" IS A PRODUCT OF S&P DOW JONES INDICES LLC OR ITS AFFILIATES ("SPDJI"), AND HAS BEEN LICENSED FOR USE BY THE MANAGER. STANDARD & POOR'S® AND S&P® ARE REGISTERED TRADEMARKS OF STANDARD & POOR'S FINANCIAL SERVICES LLC; DOW JONES® IS A REGISTERED TRADEMARK OF DOW JONES TRADEMARK HOLDINGS LLC ("DOW JONES"); AND THESE TRADEMARKS HAVE BEEN LICENSED FOR USE BY SPDJI AND SUBLICENSED FOR CERTAIN PURPOSES BY THE MANAGER. IT IS NOT POSSIBLE TO INVEST DIRECTLY IN AN INDEX. THE FUND IS NOT SPONSORED, ENDORSED, SOLD OR PROMOTED BY SPDJI, DOW JONES, S&P, ANY OF THEIR RESPECTIVE AFFILIATES (COLLECTIVELY, "S&P DOW JONES INDICES"). NEITHER S&P DOW JONES INDICES MAKE ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, TO THE OWNERS OF THE FUND OR ANY MEMBER OF THE PUBLIC REGARDING THE ADVISABILITY OF INVESTING IN SECURITIES GENERALLY OR IN THE FUND PARTICULARLY OR THE ABILITY OF THE S&P WORLD ESG ENHANCED HEALTH CARE INDEX TO TRACK GENERAL MARKET PERFORMANCE. PAST PERFORMANCE OF AN INDEX IS NOT AN INDICATION OR GUARANTEE OF FUTURE RESULTS. S&P DOW JONES INDICES' ONLY RELATIONSHIP TO THE MANAGER

WITH RESPECT TO THE S&P WORLD ESG ENHANCED HEALTH CARE INDEX IS THE LICENSING OF THE INDEX AND CERTAIN TRADEMARKS, SERVICE MARKS AND/OR TRADE NAMES OF S&P DOW JONES INDICES AND/OR ITS LICENSORS. THE S&P WORLD ESG ENHANCED HEALTH CARE INDEX IS DETERMINED, COMPOSED AND CALCULATED BY S&P DOW JONES INDICES WITHOUT REGARD TO THE MANAGER OR THE FUND. S&P DOW JONES INDICES HAVE NO OBLIGATION TO TAKE THE NEEDS OF THE MANAGER OR THE OWNERS OF THE FUND INTO CONSIDERATION IN DETERMINING, COMPOSING OR CALCULATING THE S&P WORLD ESG ENHANCED HEALTH CARE INDEX. NEITHER S&P DOW JONES INDICES ARE RESPONSIBLE FOR AND HAVE NOT PARTICIPATED IN THE DETERMINATION OF THE PRICES, AND AMOUNT OF THE FUND OR THE TIMING OF THE ISSUANCE OR SALE OF THE FUND OR IN THE DETERMINATION OR CALCULATION OF THE EQUATION BY WHICH THE FUND IS TO BE CONVERTED INTO CASH, SURRENDERED OR REDEEMED, AS THE CASE MAY BE. S&P DOW JONES INDICES HAVE NO OBLIGATION OR LIABILITY IN CONNECTION WITH THE ADMINISTRATION, MARKETING OR TRADING OF THE FUND. THERE IS NO ASSURANCE THAT INVESTMENT PRODUCTS BASED ON THE S&P WORLD ESG ENHANCED HEALTH CARE INDEX WILL ACCURATELY TRACK INDEX PERFORMANCE OR PROVIDE POSITIVE INVESTMENT RETURNS. S&P DOW JONES INDICES LLC IS NOT AN INVESTMENT OR TAX ADVISOR. A TAX ADVISOR SHOULD BE CONSULTED TO EVALUATE THE IMPACT OF ANY TAX-EXEMPT SECURITIES ON PORTFOLIOS AND THE TAX CONSEQUENCES OF MAKING ANY PARTICULAR INVESTMENT DECISION. INCLUSION OF A SECURITY WITHIN AN INDEX IS NOT A RECOMMENDATION BY S&P DOW JONES INDICES TO BUY, SELL, OR HOLD SUCH SECURITY, NOR IS IT CONSIDERED TO BE INVESTMENT ADVICE.

NEITHER S&P DOW JONES INDICES GUARANTEES THE ADEQUACY, ACCURACY, TIMELINESS AND/OR THE COMPLETENESS OF THE S&P WORLD ESG ENHANCED HEALTH CARE INDEX OR ANY DATA RELATED THERETO OR ANY COMMUNICATION, INCLUDING BUT NOT LIMITED TO, ORAL OR WRITTEN COMMUNICATION (INCLUDING ELECTRONIC COMMUNICATIONS) WITH RESPECT THERETO. S&P DOW JONES INDICES SHALL NOT BE SUBJECT TO ANY DAMAGES OR LIABILITY FOR ANY ERRORS, OMISSIONS, OR DELAYS THEREIN. S&P DOW JONES INDICES MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIMS ALL WARRANTIES, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE OR AS TO RESULTS TO BE OBTAINED BY THE MANAGER, OWNERS OF THE FUND, OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE S&P WORLD ESG ENHANCED HEALTH CARE INDEX OR WITH RESPECT TO ANY DATA RELATED THERETO. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT WHATSOEVER SHALL S&P DOW JONES INDICES BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES INCLUDING BUT NOT LIMITED TO, LOSS OF PROFITS, TRADING LOSSES, LOST TIME OR GOODWILL, EVEN IF THEY HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, WHETHER IN CONTRACT, TORT, STRICT LIABILITY, OR OTHERWISE. THERE ARE NO THIRD PARTY BENEFICIARIES OF ANY AGREEMENTS OR ARRANGEMENTS BETWEEN S&P DOW JONES INDICES AND THE MANAGER, OTHER THAN THE LICENSORS OF S&P DOW JONES INDICES.

Appendix I – Description of the Shares

Share Class	Currency	Minimum Initial Subscription**	Minimum Subscription Amount*/**	Minimum Redemption Amount**	Minimum Holding	Initial Offer Period Status	Management Fee (max)***
Acc	USD	100,000 Shares	100,000 Shares	100,000 Shares	N/A	Closed	0.18%
Dist	USD	100,000 Shares	100,000 Shares	100,000 Shares	N/A	Open	0.18%
EUR PfHdg Dist	EUR	100,000 Shares	100,000 Shares	100,000 Shares	N/A	Open	0.23%
EUR PfHdg Acc	EUR	100,000 Shares	100,000 Shares	100,000 Shares	N/A	Open	0.23%
GBP PfHdg Dist	GBP	100,000 Shares	100,000 Shares	100,000 Shares	N/A	Open	0.23%
GBP PfHdg Acc	GBP	100,000 Shares	100,000 Shares	100,000 Shares	N/A	Open	0.23%
CHF PfHdg Dist	CHF	100,000 Shares	100,000 Shares	100,000 Shares	N/A	Open	0.23%
CHF PfHdg Acc	CHF	100,000 Shares	100,000 Shares	100,000 Shares	N/A	Open	0.23%
MXN PfHdg Dist	MXN	100,000 Shares	100,000 Shares	100,000 Shares	N/A	Open	0.23%
MXN PfHdg Acc	MXN	100,000 Shares	100,000 Shares	100,000 Shares	N/A	Open	0.23%
SEK PfHdg Dist	SEK	100,000 Shares	100,000 Shares	100,000 Shares	N/A	Open	0.23%
SEK PfHdg Acc	SEK	100,000 Shares	100,000 Shares	100,000 Shares	N/A	Open	0.23%

* Minimums can be waived at the discretion of the Manager

**unless the Manager otherwise determines

***or such lower amount as may be advised to Shareholders from time to time.